Nandita Khera

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Costs of second allogeneic hematopoietic cell transplantation
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic in Arizona, Phoenix, AZ, USA
    Transplantation 96:108-15. 2013
  2. pmc Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation
    Nandita Khera
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Clin Oncol 30:71-7. 2012
  3. doi request reprint Economics of hematopoietic cell transplantation
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA
    Blood 120:1545-51. 2012
  4. pmc Clinical benefit of response in chronic graft-versus-host disease
    Yoshihiro Inamoto
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Electronic address
    Biol Blood Marrow Transplant 18:1517-24. 2012
  5. pmc Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors
    Nandita Khera
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 17:995-1003. 2011
  6. pmc Validation of measurement scales in ocular graft-versus-host disease
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ophthalmology 119:487-93. 2012
  7. pmc Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment
    Nandita Khera
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:220-8. 2012

Detail Information

Publications7

  1. pmc Costs of second allogeneic hematopoietic cell transplantation
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic in Arizona, Phoenix, AZ, USA
    Transplantation 96:108-15. 2013
    ....
  2. pmc Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation
    Nandita Khera
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Clin Oncol 30:71-7. 2012
    ..Our objective was to describe the incidence of nonmalignant late complications and their association with health and functional status in a recent cohort of hematopoietic cell transplantation (HCT) survivors...
  3. doi request reprint Economics of hematopoietic cell transplantation
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA
    Blood 120:1545-51. 2012
    ..We discuss the need for more value-based assessments of HCT using high-quality approaches to measuring costs and outcomes so that potential future efforts to contain costs are well informed and appropriate...
  4. pmc Clinical benefit of response in chronic graft-versus-host disease
    Yoshihiro Inamoto
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Electronic address
    Biol Blood Marrow Transplant 18:1517-24. 2012
    ..Modification of the algorithm or validation of other more meaningful clinical endpoints is warranted for future clinical trials of treatment for chronic graft-versus-host disease...
  5. pmc Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors
    Nandita Khera
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 17:995-1003. 2011
    ..Future efforts to improve adherence should address concerns about medical costs and lack of knowledge, two major modifiable predictors of lower adherence to preventive care practices in HCT survivors...
  6. pmc Validation of measurement scales in ocular graft-versus-host disease
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ophthalmology 119:487-93. 2012
    ..Candidate scales were recommended for use in clinical trials by the National Institutes of Health (NIH) Chronic GVHD Consensus Conference or have been previously validated in dry eye syndromes...
  7. pmc Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment
    Nandita Khera
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:220-8. 2012
    ..We conclude that limiting the daily TNC dose improved the safety of this procedure without compromising engraftment or increasing the costs of the procedure...